A new insight on feasibility of pre-, pro-, and synbiotics-based therapies in Alzheimer’s disease

IF 0.7 Q4 PHARMACOLOGY & PHARMACY
M. Talebi, Vida Ebrahimi, Ahmadreza Rasouli, Afasneh Farjami, Saiedeh Razi Soofiyani, Alireza Soleimanian, Haleh Forouhandeh, Vahideh Tarhriz
{"title":"A new insight on feasibility of pre-, pro-, and synbiotics-based therapies in Alzheimer’s disease","authors":"M. Talebi, Vida Ebrahimi, Ahmadreza Rasouli, Afasneh Farjami, Saiedeh Razi Soofiyani, Alireza Soleimanian, Haleh Forouhandeh, Vahideh Tarhriz","doi":"10.4103/jrptps.jrptps_170_21","DOIUrl":null,"url":null,"abstract":"Alzheimer’s disease is a prevalent cause of dementia in the elderly population. The existing treatments in this issue are limited in efficacy besides having several adverse effects. Therefore, developing new therapeutic strategies is a major concern of scientists. This disease is closely linked to gut microflora through the brain–gut–microbiota axis. Targeting gut microbiota by pre-, pro-, and synbiotics supplementation can be effective for its treatment. Herein, we discuss the protecting effects of pre-, pro-, and synbiotics products against Alzheimer’s disease based on comprehensive assessment of animal studies and performed clinical trials. Primarily, we briefly introduced involved pathogenesis, probable drug targets, and its correlation with gut microbiota. Subsequently, we debated preclinical and clinical research studies on the effect of pre-, pro-, and synbiotics agents on brain functionality, metabolic features, and biomarkers that are proven to have therapeutic effects. Searching the online databases revealed therapeutic capabilities of pre-, pro-, and synbiotics in Alzheimer’s disease treatment by some mechanisms such as anti-oxidative stress, anti-inflammatory, prohibiting of apoptosis and DNA damage, insulin regulation, suppressing the aggregation of beta-amyloid (Aβ) and tau proteins, which can be considered as important outcomes of this application.","PeriodicalId":16966,"journal":{"name":"Journal of Reports in Pharmaceutical Sciences","volume":"11 1","pages":"141 - 155"},"PeriodicalIF":0.7000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Reports in Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrptps.jrptps_170_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Alzheimer’s disease is a prevalent cause of dementia in the elderly population. The existing treatments in this issue are limited in efficacy besides having several adverse effects. Therefore, developing new therapeutic strategies is a major concern of scientists. This disease is closely linked to gut microflora through the brain–gut–microbiota axis. Targeting gut microbiota by pre-, pro-, and synbiotics supplementation can be effective for its treatment. Herein, we discuss the protecting effects of pre-, pro-, and synbiotics products against Alzheimer’s disease based on comprehensive assessment of animal studies and performed clinical trials. Primarily, we briefly introduced involved pathogenesis, probable drug targets, and its correlation with gut microbiota. Subsequently, we debated preclinical and clinical research studies on the effect of pre-, pro-, and synbiotics agents on brain functionality, metabolic features, and biomarkers that are proven to have therapeutic effects. Searching the online databases revealed therapeutic capabilities of pre-, pro-, and synbiotics in Alzheimer’s disease treatment by some mechanisms such as anti-oxidative stress, anti-inflammatory, prohibiting of apoptosis and DNA damage, insulin regulation, suppressing the aggregation of beta-amyloid (Aβ) and tau proteins, which can be considered as important outcomes of this application.
关于阿尔茨海默病前、前和合成药物治疗可行性的新见解
阿尔茨海默病是老年痴呆症的普遍病因。现有的治疗方法除了有一些不良反应外,疗效有限。因此,开发新的治疗策略是科学家们关注的主要问题。这种疾病通过脑-肠-菌群轴与肠道菌群密切相关。针对肠道微生物群,通过前,前和合成补充可以有效地治疗。在此,我们在动物研究和临床试验的综合评估基础上,讨论了前置、前置和合成产品对阿尔茨海默病的保护作用。首先,我们简要介绍了其发病机制、可能的药物靶点及其与肠道菌群的关系。随后,我们对临床前和临床研究进行了辩论,这些研究涉及前、前和合成制剂对脑功能、代谢特征和已被证明具有治疗作用的生物标志物的影响。通过对在线数据库的搜索,我们发现了pre-、pre-和synbiotics在阿尔茨海默病治疗中的一些机制,如抗氧化应激、抗炎、禁止细胞凋亡和DNA损伤、胰岛素调节、抑制β -淀粉样蛋白(Aβ)和tau蛋白的聚集,这些可以被认为是该应用的重要结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Reports in Pharmaceutical Sciences
Journal of Reports in Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
1.40
自引率
0.00%
发文量
0
期刊介绍: The Journal of Reports in Pharmaceutical Sciences(JRPS) is a biannually peer-reviewed multi-disciplinary pharmaceutical publication to serve as a means for scientific information exchange in the international pharmaceutical forum. It accepts novel findings that contribute to advancement of scientific knowledge in pharmaceutical fields that not published or under consideration for publication anywhere else for publication in JRPS as original research article. all aspects of pharmaceutical sciences consist of medicinal chemistry, molecular modeling, drug design, pharmaceutics, biopharmacy, pharmaceutical nanotechnology, pharmacognosy, natural products, pharmaceutical biotechnology, pharmacology, toxicology and clinical pharmacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信